Abstract
No public abstract is available from the verified source records.
Nishi Yadav, Lynda Little-Ihrig, Joseph D. Latoche, Kathryn E. Day, Kanishka Sikligar, Sina Tavakoli, Enrico M. Novelli, Carolyn J. Anderson
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology
10.1182/blood.v77.2.214.214 · 1991
Pathophysiology of stroke in sickle cell disease
10.1080/10739680490278600 · 2004
Pathogenesis and treatment of sickle cell disease
10.1056/nejm199709113371107 · 1997
Crises in sickle cell disease
10.1016/j.chest.2015.12.016 · 2016
(1993) Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium
10.1182/blood.v82.6.1891.1891 · 1993
Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia
10.1182/blood.v82.12.3548.3548 · 1993
PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates
10.2967/jnumed.114.144881 · 2014
Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-targeted PET imaging and treatment of metastatic melanoma
10.1021/mp5006917 · 2015
Combination treatment of VLA-4 targeted radionuclide therapy and immunotherapy in a mouse model of melanoma
10.2967/jnumed.118.209510 · 2018
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice
10.1182/bloodadvances.2020002642 · 2020
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model
10.3324/haematol.2010.023325 · 2010
Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia
10.3324/haematol.2017.177360 · 2018
Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease
10.1046/j.1365-2141.2002.03274.x · 2002
A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea
10.1182/blood.2024028136 · 2025
Hydroxyurea decouples persistent F-cell elevation and induction of γ-globin
10.1016/j.exphem.2022.07.005 · 2022
Blood-borne lipopolysaccharide is rapidly eliminated by liver sinusoidal endothelial cells via high-density lipoprotein
10.4049/jimmunol.1600702 · 2016
Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease
10.1371/journal.pone.0226583 · 2019
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin
10.1182/blood-2011-08-374447 · 2012
Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype
10.1016/j.bcmd.2008.08.003 · 2009
Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa
10.1056/nejmoa1813598 · 2009
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea
10.1182/blood-2014-12-616250 · 2015
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice
10.1182/blood-2012-02-409524 · 2012
No additional external references are available.